News

FDA approves expanded use of Moderna’s RSV shot, but uncertainty remains
The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...
Newly approved antibody could offer another option for protecting infants from RSV, a common infection that can be deadly
The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...
The Manhattan Mercury2d
New Antibody Shot Could Help Protect Babies From RSV
THURSDAY, June 12, 2025 (HealthDay News) — A newly approved shot could soon help protect babies from respiratory syncytial ...
FDA clears Moderna’s RSV vaccine for use in people ages 18 to 59
The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...
hMPV is likely one of the viruses making us sick this winter. Here’s what to know about human metapneumovirus
MPV tends to hit hardest in young children, older adults and people with weakened immune systems. A virologist explains.
BioPharma Dive1d
Moderna wins FDA OK to widen use of RSV vaccine
The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s ...
BioSpace2d
As New CDC Vaccine Advisors Gear Up for First Meeting, Experts Ask, ‘Where’s Cassidy?’
Scientists and analysts express concern that the newly appointed members—which include known anti-vaxxers—could relitigate ...
Global Respiratory Syncytial Virus Treatment Market Size To Reach USD 8,332.5 Million By 2033 Astute Analytica
The global respiratory syncytial virus respiratory syncytial virus treatment market is undergoing rapid growth, driven by rising vaccine uptake, impr ...
STAT1d
FDA clears Moderna’s RSV vaccine for use in people aged 18 to 59
The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.